Active	Status	Sponsor type	Region	Phase	Filter
11 Active 2 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Milewski, Krzysztof
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Active, not recruiting	3	17300	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06383390 / 2023-508630-34-00: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Active, not recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
BIPASS-AKI, NCT05990660: Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery	Completed	N/A	10	Europe, RoW	JuxtaFlow System	3ive Labs, SCIRENT	Renal Insufficiency, Acute Kidney Injury	12/23	01/24
LAAOS-4, NCT05963698: The Fourth Left Atrial Appendage Occlusion Study	Recruiting	N/A	4000	Europe, Canada, US	WATCHMAN device	Hamilton Health Sciences Corporation, McMaster University, Population Health Research Institute, Boston Scientific Corporation	Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism	09/29	12/29
Okniński, Antoni
No trials found